

HLDA9 ANTIBODY VALIDATION FILE

ANTIBODY INFORMATION

Antibody Name: E10-286

Specificity: CD329

Antibody species: Mouse

Ig Isotype: IgG1 (Kappa)

Immunogen:

Epitope recognized:

Submitter: BD Pharmigen


INFORMATION FOR CONFIRMATION OF SPECIFICITY:

Expression on transfected COS: positive. (Fig. 1A)

Expression on the cell- surface of cell line: Negative. (Fig. 1B)

Expression on cell- surface of normal cell: positive with PBL's Monocyte cells. (Fig. 1C)

Figure 1:



Reactivity of CD329 with cell lines

	Cell lines	CD329
EBV-transformed B cells	CESS	-
Burkitt lymphoma B cell lines	Raji	-
	Daudi	-
	Namalwa	-
	Ramos	-
Multiple myeloma	RPMI8226	-
T cell leukemia	Jurkat	-
	HSB2	-
NK cell leukemia	YT	-
Myeloid leukemia	HL-60	-
	K-562	-
	U-937	-

Reactivity of CD329 with PBL

Lymphocytes	-
Granulocytes	-
Monocytes	++++

INFORMATION PROVIDED BY SUBMITTER

Publications:

von Gunten S, Schaub A, Vogel M, Stadler BM, Miescher S, Simon HU. Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. *Blood*. 2006 Dec 15;108(13):4255-9. Epub 2006 Aug 10.

Carlin AF, Uchiyama S, Chang YC, Lewis AL, Nizet V, Varki A. Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response. *Blood*. 2009 Apr 2;113(14):3333-6. Epub 2009 Feb 4.

Carlin AF, Lewis AL, Varki A, Nizet V. Group B streptococcal capsular sialic acids interact with siglecs (immunoglobulin-like lectins) on human leukocytes. *J Bacteriol*. 2007 Feb;189(4):1231-7. Epub 2006 Sep 22.

Nguyen DH, Hurtado-Ziola N, Gagneux P, Varki A. Loss of Siglec expression on T lymphocytes during human evolution. *Proc Natl Acad Sci U S A*. 2006 May 16;103(20):7765-70. Epub 2006 May 8

Patents:

Licensed to a company and which one:

Was it evaluated in a previous workshop?